Acorda Therapeutics (ACOR) Misses Q3 EPS by 15c; Reiterates AMPYRA Net Sales Guidance
Tweet
Share
E-mailGet Alerts ACOR Hot Sheet
Price: $0.66 --0%
Revenue Growth %: +63.1%
Financial Fact:
Selling, general and administrative: 54.81M
Today's EPS Names:
SFST, VLTO, CLIR, More
Revenue Growth %: +63.1%
Financial Fact:
Selling, general and administrative: 54.81M
Today's EPS Names:
SFST, VLTO, CLIR, More
Join SI Premium – FREE
Acorda Therapeutics (NASDAQ: ACOR) reported Q3 EPS of ($0.04), $0.15 worse than the analyst estimate of $0.11. Revenue for the quarter came in at $135.61 million versus the consensus estimate of $134.01 million.
The Company is reiterating 2016 AMPYRA net sales guidance of $475-$485 million.
For earnings history and earnings-related data on Acorda Therapeutics (ACOR) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Tesla touts acceleration of new models, but Q1 results fall short of estimates
- Weatherford International plc (WFRD) Tops Q1 EPS by 6c
- Visa (V) Tops Q2 EPS by 7c, offers guidance
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
